Brind.

FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.

9 reports, 6 independent Updated Aug 28
Gone quiet Reached 6 outlets in its first 24 hours
Reports
9
Developments
3
Repetition
78%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 6 independent outlets

FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.

Who's involved

What this event is mainly about
FDANovavaxSanofi

How it developed

Newest first. Tap a step to see who reported it.
  1. Novavax and Sanofi announced a partnership to facilitate vaccine access.Sub-event
  2. Novavax received FDA approval for Nuvaxovid, and leadership of U.S. commercial operations transferred to Sanofi.1 source
  3. RFK Jr.'s policy shift led to project cancellations as Novavax transitioned Nuvaxovid leadership to Sanofi.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLA We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Novavax, Inc. is one of them. Novavax, Inc. (NASDA
  • Simply Wall St.Novavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's Changed On August 27, 2025, Novavax announced that the U.S. FDA approved the Nuvaxovid 2025-2026 COVID-19 vac
  • Insider MonkeyNovavax, Inc. (NVAX) Launches Protein-Based Vaccine for High-Risk Adults We recently published 10 Best Biotech Stocks to Buy Under $10. Novavax, Inc. is one of them. Novavax, Inc. (NASDAQ:NVAX) is a
  • ZacksNVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View Novavax NVAX reported second-quarter 2025 earnings per share (EPS) of 62 cents against the Zacks Consensus Estimate of a loss of seven
  • Investing.comNovavax lifts 2025 revenue outlook after FDA milestone payment Investing.com -- Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi
  • BenzingaNovavax Ups Outlook, Eyes Stronger Nuvaxovid Sales On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the con
  • PR NewswireNovavax Reports Second Quarter 2025 Financial Results and Operational Highlights Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombi
2 more outlets ran the same wire story